Simon F. Lacey

38.1k total citations · 8 hit papers
157 papers, 15.0k citations indexed

About

Simon F. Lacey is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Simon F. Lacey has authored 157 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Oncology, 50 papers in Immunology and 35 papers in Epidemiology. Recurrent topics in Simon F. Lacey's work include CAR-T cell therapy research (94 papers), Immune Cell Function and Interaction (29 papers) and Cytomegalovirus and herpesvirus research (29 papers). Simon F. Lacey is often cited by papers focused on CAR-T cell therapy research (94 papers), Immune Cell Function and Interaction (29 papers) and Cytomegalovirus and herpesvirus research (29 papers). Simon F. Lacey collaborates with scholars based in United States, France and United Kingdom. Simon F. Lacey's co-authors include Carl H. June, J. Joseph Melenhorst, Bruce L. Levine, Stephan A. Grupp, David L. Porter, Noelle V. Frey, Pamela A. Shaw, Shannon L. Maude, Zhaohui Zheng and Vanessa Gonzalez and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Simon F. Lacey

157 papers receiving 14.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

2014 3.9k citations Shannon L. Maude, Noelle V. Frey et al. profile →
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

2015 1.3k citations David Porter, Wei‐Ting Hwang et al. Science Translational Medicine profile →
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

2017 1.3k citations Stephen J. Schuster, Jakub Svoboda et al. profile →
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

2018 478 citations Fang Chen, J. Joseph Melenhorst et al. Molecular Therapy profile →
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

2015 434 citations Alfred L. Garfall, Marcela V. Maus et al. profile →
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation

2018 430 citations Avery D. Posey, Prachi Patel et al. profile →
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

2018 379 citations Simon F. Lacey, Farzana Nazimuddin et al. profile →
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

2016 344 citations Shannon L. Maude, David M. Barrett et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon F. Lacey United States	50	11.9k	4.5k	3.9k	3.6k	3.3k	157	15.0k
Barbara Savoldo United States	66	14.0k 1.2×	6.5k 1.5×	4.4k 1.1×	4.8k 1.3×	3.8k 1.2×	207	16.6k
Michael Kalos United States	39	11.7k 1.0×	6.0k 1.3×	4.9k 1.3×	4.1k 1.2×	2.8k 0.8×	97	15.5k
Michael C. Milone United States	46	11.5k 1.0×	5.8k 1.3×	4.5k 1.2×	3.5k 1.0×	3.6k 1.1×	136	15.6k
Cameron J. Turtle United States	48	8.7k 0.7×	3.8k 0.8×	3.0k 0.8×	2.4k 0.7×	2.3k 0.7×	167	11.8k
Terry J. Fry United States	49	8.5k 0.7×	6.2k 1.4×	2.8k 0.7×	2.5k 0.7×	2.1k 0.6×	193	13.1k
Stephen Gottschalk United States	64	9.4k 0.8×	4.7k 1.1×	3.0k 0.8×	3.1k 0.9×	2.1k 0.6×	256	12.2k
Steven A. Feldman United States	36	9.6k 0.8×	4.7k 1.0×	3.1k 0.8×	3.0k 0.8×	2.3k 0.7×	87	11.4k
Crystal L. Mackall United States	50	9.7k 0.8×	4.9k 1.1×	3.6k 0.9×	2.5k 0.7×	2.8k 0.8×	154	12.9k
Adrian P. Gee United States	56	9.6k 0.8×	5.3k 1.2×	3.2k 0.8×	3.4k 1.0×	1.9k 0.6×	222	14.5k

Countries citing papers authored by Simon F. Lacey

Since Specialization

Citations

This map shows the geographic impact of Simon F. Lacey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon F. Lacey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon F. Lacey more than expected).

Fields of papers citing papers by Simon F. Lacey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon F. Lacey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon F. Lacey. The network helps show where Simon F. Lacey may publish in the future.

Co-authorship network of co-authors of Simon F. Lacey

This figure shows the co-authorship network connecting the top 25 collaborators of Simon F. Lacey. A scholar is included among the top collaborators of Simon F. Lacey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon F. Lacey. Simon F. Lacey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jung, In-Young, Vivek Narayan, Andrew J. Rech, et al.. (2022). BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Science Translational Medicine. 14(670). eabn7336–eabn7336. 82 indexed citations

Cohen, Adam D., Simon F. Lacey, Megan M. Davis, et al.. (2021). The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research. 27(23). 6580–6590. 23 indexed citations

Jacobson, Jeffrey M., Julie K. Jadlowsky, Simon F. Lacey, et al.. (2020). Autologous CD4 T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular Therapy. 29(2). 626–635. 5 indexed citations

Ruella, Marco, David M. Barrett, Olga Shestova, et al.. (2019). A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells. Blood. 135(7). 505–509. 24 indexed citations

Ghassemi, Saba, Selene Nuñez-Cruz, Roddy S. O’Connor, et al.. (2018). Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer Immunology Research. 6(9). 1100–1109. 212 indexed citations

Leibman, Rachel S., Max W. Richardson, Christoph T. Ellebrecht, et al.. (2017). Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathogens. 13(10). e1006613–e1006613. 94 indexed citations

Cummins, Katherine D., Noelle V. Frey, Anne Marie Nelson, et al.. (2017). Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells. Blood. 130. 1359–1359. 92 indexed citations

Chong, Elise A., J. Joseph Melenhorst, Jakub Svoboda, et al.. (2017). Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy. Blood. 130. 4121–4121. 17 indexed citations

Portnow, Jana, Timothy W. Synold, Behnam Badie, et al.. (2016). Neural Stem Cell–Based Anticancer Gene Therapy: A First-in-Human Study in Recurrent High-Grade Glioma Patients. Clinical Cancer Research. 23(12). 2951–2960. 127 indexed citations

10.

Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research. 22(11). 2684–2696. 141 indexed citations

11.

Chen, Fangfang, David T. Teachey, Edward Pequignot, et al.. (2016). Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. Journal of Immunological Methods. 434. 1–8. 141 indexed citations

12.

Ruella, Marco, Saad S. Kenderian, Olga Shestova, et al.. (2016). Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms. Blood. 128(22). 2159–2159. 8 indexed citations

13.

Kenderian, Saad S., Marco Ruella, Olga Shestova, et al.. (2016). Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model. Blood. 128(22). 652–652. 31 indexed citations

14.

Rheingold, Susan R., Shannon L. Maude, Richard Aplenc, et al.. (2015). Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. Blood. 126(23). 3769–3769. 35 indexed citations

15.

Kalos, Michael, Farzana Nazimuddin, Jeffrey Finklestein, et al.. (2013). Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19. Blood. 122(21). 163–163. 18 indexed citations

16.

Husseiny, Mohamed I. & Simon F. Lacey. (2011). Development of infectious recombinant BK virus. Virus Research. 161(2). 150–161. 6 indexed citations

17.

Krishnan, Aparna, Wendi Zhou, Simon F. Lacey, et al.. (2010). Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease. Transplant Infectious Disease. 12(4). 363–370. 25 indexed citations

18.

Zhou, Wendi, Joy Martinez, Tumul Srivastava, et al.. (2007). Functional Characterization of BK Virus-Specific CD4 ⁺ T Cells with Cytotoxic Potential in Seropositive Adults. Viral Immunology. 20(3). 379–388. 74 indexed citations

19.

Lacey, Simon F., Corinna La Rosa, Wendy Zhou, et al.. (2006). Functional Comparison of T Cells Recognizing Cytomegalovirus pp65 and Intermediate‐Early Antigen Polypeptides in Hematopoietic Stem‐Cell Transplant and Solid Organ Transplant Recipients. The Journal of Infectious Diseases. 194(10). 1410–1421. 42 indexed citations

20.

Gallez‐Hawkins, Ghislaine, Xiuli Li, Anne Franck, et al.. (2004). DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine. 23(6). 819–826. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact